FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Wash	ington,	D.C.	20549	

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average b	ourden						
hours per response:	0.5						

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>CALHOUN CHRISTOPHER J</u>					2. Issuer Name and Ticker or Trading Symbol CYTORI THERAPEUTICS, INC. [CYTX]									k all applica	tionship of Reporting Pers all applicable) Director		son(s) to Issuer 10% Owner	
(Last) 3020 CA	(F LLAN RO	First)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 01/31/2013								X	Officer (give title below) Chief Executive Officer				
(Street)	EGO C	ČA	92121		4. If Am	endment,	Date (of Original	Filed	(Month/Day	y/Year)		6. Ind Line) X	Form fil	ed by One	e Repoi	(Check Appl rting Person One Reporti	
(City)	(5	State)	(Zip)								D.		- 11					
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date,		3. Transaction Code (Instr.		4. Securit	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and			5. Amoun Securities Beneficia Owned Fo	s Ily	Form:	Direct II	7. Nature of Indirect Beneficial Ownership	
									v	Amount	(A) (D)	or Pric	се	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)
Restricted Stock (Common Stock)			01/31/2013				D		21,105	5 ⁽¹⁾ D		\$ <mark>0</mark>	147,270		D			
Common Stock												36,	850		I 4	By 101(k) Plan		
			Table II -							osed of, convertil				wned				
Derivative Conversion Date		3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	Code	Transaction Code (Instr.		Derivative Ex		6. Date Exercisable and Expiration Date Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securitie Beneficia Owned Following Reported	e s ally g i	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	Amou or Numb of Sha	er		Transaction(s) (Instr. 4)			
Employee Stock Option	\$2.74	01/31/2013		A		250,000		02/28/201	3 ⁽²⁾	01/31/2023	Common Stock	250,0	000	\$0	1,235,0	000	D	
Employee Stock	\$5	01/31/2013		A		125,000		02/28/201	3 ⁽²⁾	01/31/2023	Common Stock	125,0	000	\$0	1,360,0	000	D	

Explanation of Responses:

1. On January 31st, 2013 the Compensation Committee of the Board of Directors determined that 58% of the performance goals for the 2012 performance conditioned restricted stock grant were achieved, and that such percentage of shares granted will continue to time vest through January 10, 2014. The remaining portion of the 2012 performance grant shares (42%) are no longer qualified to continue vesting and have been cancelled. The disposition of these cancelled shares is reflected in Table I above.

Remarks:

Jonathan E. Soneff, By Power 02/04/2013 of Attorney For: Christopher J. Calhoun

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{2.} The Employee Stock options vest 1/48th each month from date of grant.